ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
BMS acquires Celgene for an equity value of $74bn pharmaceutical-technology
January 04, 2019Bristol-Myers Squibb (BMS) has entered into a definitive merger agreement to acquire Celgene via a cash and stock transaction with an equity value of $74bn; Celgene shares have been valued at $102.43 per share....
Pharma Sources Insight July 2025
